Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityNo recent work listed

Meifang He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1225-0766; OpenAlex author ID A5019580460. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper

Papers 4

  1. Serum aspartate aminotransferase is an adverse prognostic indicator for patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/labmed/lmad014↗
  2. Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adeno… First author DOI 10.1038/s41392-020-00346-w↗
  3. GOLPH3 Promotes Cancer Growth by Interacting With STIP1 and Regulating Telomerase Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.575358↗
  4. Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2018.6703↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen Li Ma · 3 shared papers, 2018–2020 · strength 0.30
  2. Dong Wang · 2 shared papers, 2018–2023 · strength 0.29
  3. Kebing Wang · 2 shared papers, 2018–2020 · strength 0.19
  4. Qiang Sun · 1 shared paper, 2020 · strength 0.11
  5. Hongyan Huang · 1 shared paper, 2020 · strength 0.11
  6. Yanbin Zhang · 1 shared paper, 2020 · strength 0.11
  7. Zhi Li · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.